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ABSTRACT
The new coronavirus, COVID-19 was declared a pandemic by the World Health 
Organization on March 11, 2020. Risk factors associated with this disease are age, sex, and the 
presence of comorbidities, the most common being hypertension, diabetes, and heart disease. 
The aim of this meta-analysis was to calculate the prevalence and geographical distribution of 
comorbidities in all patients admitted to intensive care units (ICUs), and the mortality rate of 
COVID-19. We selected studies based upon epidemiological and clinical descriptions of the 
patients and mortality from the disease to determine the pooled prevalence of comorbidities 
in all patients and in mortality cases due to COVID-19. The pooled prevalence was estimated 
using the random effects model, and odds ratios were used to measure the probability of 
death for a patient with a comorbidity. The total prevalence of comorbidities in patients with 
COVID-19 was 42% (95% CI: 25-60), 61% (95% CI: 42-80) in those admitted to the ICU, 
and 77% (95% CI: 68-86) among death cases; males were the most affected. Hypertension 
was the most prevalent comorbidity in all three groups studied, accounting for 32%, 26%, 
and 35%, respectively. The odds ratio of death for a patient with a comorbidity compared to 
one with no comorbidity was 2.4 (P < 0.0001). The higher the prevalence of comorbidities 
the higher the odds that the COVID-19 patient will need intensive care or will die, especially 
if the pre-existing disease is hypertension, heart disease, or diabetes.
KEYWORDS: COVID-19. SARS-CoV2. Prevalence. Comorbidity. Mortality. Meta-analysis. 
INTRODUCTION
The 2019 pandemic coronavirus (COVID-19) has affected more than three 
million people in 211 countries, causing more than two hundred thousand deaths 
as of the end of April 20201. The etiologic agent of this disease is the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV2), which is transmitted through 
contact with infected persons or contaminated fluids2,3. 
Several risk factors are associated with this disease. In a multicenter cohort 
study, advanced age was found to be significantly correlated with overall COVID-19 
prevalence, which is consistent with the higher incidence observed in older adults4. 
The sex is another risk factor as a higher prevalence has been seen in men than 
women4. Other studies have shown that the presence of any comorbidity increases 
the chances of COVID-19 infection causing respiratory failure and death in 
patients5. Another study reports that patients admitted to the intensive care unit 
(ICU) had a higher number of comorbidities (72.2%) than those not admitted to 
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the ICU (37.3%)6. Hence, comorbidities are considered a 
risk factor for fatality, and data from other reports show up 
to a 90% prevalence of comorbidities in fatal cases7, with 
cardiovascular diseases, diabetes, hypertension, chronic 
obstructive pulmonary disease being the most prevalent 
known comorbidities in COVID-19 cases8. 
Currently, several published studies describe the 
epidemiological and clinical characteristics of patients and 
mortality cases affected by COVID-19 in different parts of 
the world. For this reason, the aim of this meta-analysis was 
to estimate the prevalence and geographical distribution of 
comorbidities in all patients, in those admitted to the ICU, 
and in mortality cases affected by COVID-19 using the 
previously published data.
METHODS
The protocol for this systematic review was published 
in the International Prospective Registry of Systematic 
Reviews (PROSPERO 2020: CRD42020182479) before 
its implementation. The protocol and the final report were 
developed based on the Cochrane Manual of Systematic 
Reviews of Interventions9.
Review question
What is the prevalence of comorbidities in all patients, 
patients admitted to the ICU, and in fatal cases affected by 
the new coronavirus (COVID-19)?
Inclusion criteria
This review considered studies that conducted 
epidemiological and clinical descriptions in patients and 
in fatal cases from different parts of the world, in order to 
determine the prevalence and geographic distribution of 
comorbidities in patients affected by COVID-19.
Search strategy
An initial search limited to MEDLINE was performed 
using MeSH index terms and related keywords. This search 
was followed by an analysis of the words in the text of the 
title, abstract, and index terms used to describe the articles. 
A second search using all the identified keywords and index 
terms was conducted on May 15, 2020 using the following 
databases: Latin American and Caribbean Health Sciences 
Literature (LILACS), the bibliographic database of the 
US National of Medicine (Medline), the Elsevier database 
(EMBASE), Web of Science and SCOPUS. The MeSH 
Index Term search included COVID-19, SARS-CoV2, 
prevalence, and comorbidity. As COVID-19 is a recent 
topic, thesis and dissertation papers have not yet been 
published and were not evaluated. 
Methodological quality assessment
The articles selected for data recovery were analyzed by 
two independent reviewers who assessed the methodological 
validity of each text before their inclusion in this review. The 
quality of the publications included were evaluated based on 
the criteria derived from the Grading of Recommendations 
Assessment, Development and Evaluation method 
(GRADE). Points were awarded to the studies if they did 
not present limitations in study design or execution (risk of 
bias), inconsistency of results, evidence based on indirect 
data, imprecision, and publication bias. A score of four to 
five points was considered as high quality, three points as 
moderate quality, and zero to two points as low quality.
Data extraction
The data were added to the Review Manager 
(RevMan 5.3) for analysis. A data extraction table was 
created to assess the quality of demographic data, study 
location, sample size, number of cases, number of positives 
and the diagnostic test.
Data synthesis
The random-effect model meta-analysis method was 
used to analyze the pooled prevalence of comorbidities 
in patients and in fatal cases affected by COVID-19 in 
different parts of the world. The heterogeneity among the 
studies was analyzed using the Higgins test (I2) that shows 
the percentage of variation among studies. These analyses 
were compiled by using the STATA software, version 12 
(StataCorp LLC, Texas, USA). The Odds Ratio test, with 
a 95% Confidence Interval (95% CI), was calculated 
to measure the likelihood of death for a patient with a 
comorbidity compared to a patient without comorbidities.
RESULTS
Our search resulted in 1,150 manuscripts related to the 
search strategies used. The search strategy used for each 
database was: BVS (Comorbidades OR Comorbidities 
OR Comorbilidades) AND ((“Infecções por Coronavirus” 
OR “Coronavirus Infections” OR “Infecciones por 
Coronavirus”) OR (Betacoronavirus OR Betacoronavirus 
OR Betacoronavirus) OR (COVID-19) OR (SARS-CoV2)); 
PUBMED (Comorbidity OR Comorbidities) AND 
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(“Coronavirus Infections” OR Betacoronavirus OR 
COVID-19 OR SARS-CoV2); CINAHL (Comorbidity 
OR Comorbidities) AND (“Coronavirus Infections” OR 
Betacoronavirus OR COVID-19 OR SARS-CoV2); EMBASE 
2 (‘comorbidity’/exp OR comorbidity OR ‘comorbidities’/
exp OR comorbidities) AND (‘coronavirus infection’/
exp OR ‘coronavirus infection’ OR ‘betacoronavirus’/exp 
OR betacoronavirus OR’ COVID 19’/exp OR ‘ COVID 
19’ OR ‘sars cov2’); WEB OF SCIENCE (Comorbidit* 
AND (“Coronavirus Infections” OR Betacoronavirus OR 
COVID-19 OR SARS-CoV2); SCOPUS (Comorbidit* 
AND (“Coronavirus Infections” OR Betacoronavirus OR 
COVID-19 OR SARS-CoV2). 
After applying the eligibility exclusion criteria 
(duplicate texts, articles related to other topics, text excluded 
by the review criteria or method quality), 42 studies were 
considered for analyses5-7,10-48. Of them, 39 were used to 
calculate the total prevalence of comorbidities in patients 
affected by COVID-19, six were used to calculate the 
prevalence of comorbidities in patients admitted to the ICU, 
and 11 were used to calculate the comorbidity prevalence 
in fatal cases. The characteristics of the studies included 
in this meta-analysis are shown in Table 1. The results 
of the search strategy are shown in a PRISMA flow chart 
(Figure 1). The data extracted from the final selection are 
shown in the Supplementary Table S1.
According to the criteria applied based on GRADE, 
the studies that met the selection criteria presented high 
methodological quality with a score of five. The I2 test 
indicated a low heterogeneity among the studies. Publication 
bias was not evaluated because the currently available 
methods are not considered useful for studies on proportions. 
The summaries of methodological quality and bias risk and 
applicability for each study and among the included studies 
are shown in the Supplementary Figures S1 and S2.
Overall prevalence of comorbidities
In the 39 studies used to calculate the pooled prevalence 
of comorbidities, 89,238 patients affected by COVID-19 
were analyzed; 11,341 (12.7%) presented one or more 
comorbidities, 2,172 (2.4%) were admitted to the ICU, and 
3,532 (4 %) patients died. The patients age range was 41 to 
70 years. Among these studies, only one was conducted in 
the USA43, and included a large number of patients (74,439) 
but did not segregate patients according to sex. In the other 
38 studies, 14,844 patients were registered with a total 
of 8,518 (57.4%) males and 6,413 (42.6%) females. The 
reported comorbidities included hypertension, heart disease, 
diabetes, cancer, chronic obstructive pulmonary disease, 
asthma, chronic diseases of the liver, kidneys, digestive 
system, autoimmune disorders, immunodeficiencies, stroke, 
and others. Only one study specified which diseases were 
included in the category “Others”.
Regarding the geographical distribution of the studied 
patients, 80,139 (88.7%) were in the USA and 9,051 
Figure 1 - A flowchart of the steps performed in the systematic review.
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Table 1 - A summary of the included studies.
Study Country Total ICU Death M F Co % H % CV % D % COPD %
Chen et al.5 China 99 N.S. 11 67 32 50.5 0.0 +40 0.0 1.0
Wang et al.6 China 138 36 6 75 63 46.4 31.2 14.5 10.1 2.9
CDC Korea7 Korea 54 N.S. 54 33 21 90.7 0.0 59.3 29.6 13.0
Cheng et al.10 China 698 138 113 367 331 42.6 33.4 0.0 14.3 1.9
Huang et al.11 China 41 13 N.S. 30 11 31.7 15.0 6.0 8.0 1.0
Liu et al.12 China 137 13 16 61 76 19.7 9.5 7.3 10.2 17.5
Liu et al.13 China 12 6 N.S. 7 5 58.3 25.0 33.3 16.6 8.3
Guan et al.14 China 1099 33 15 640 459 23.7 15.0 2.5 7.4 1.1
Du et al.15 China 109 51 72 74 35 78.0 59.6 +33.9 31.2 15.6
Guan et al.16 China 1590 99 50 904 686 25.0 20.3 3.8 9.0 1.5
Xu et al.17 China 63 1 0 36 27 31.7 8.0 0.0 2.0 2.0
Chen et al.18 China 203 N.S. 26 108 95 43.3 12.9 3,4 2.7 3.9
Liang et al.19 China 1590 90 50 904 674 25.1 16.9 3.7 8.2 1.5
Wang et al.20 China 399 N.S. 65 226 173 60.7 40.8 17.7 16.0 6.2
Cao et al.21 China 102 N.S. 17 53 49 46.1 27.5 4.9 10.8 9.8
Zhou et al.22 China 191 50 54 119 72 47.6 30.0 8.0 19.0 3.0
Zhang et al.23 China 120 N.S. 7 43 77 26.7 16.0 8.0 6.0 3.0
Chen et al.24 China 274 N.S. 113 171 103 48.5 34.0 8.0 17 7.0
Zhang et al.25 China 140 N.S. N.S. 71 69 64.3 30.0 5.0 12.1 1.4
Wang et al.26 China 69 N.S. 5 32 37 36.2 13.0 12.0 10.0 6.0
Yang et al.27 China 52 37 32 35 17 40.4 0.0 10.0 17.0 8.0
Wu et al.28 China 201 53 44 128 73 32.8 19.4 4.0 10.9 2.5
Huang et al.29 China 34 8 N.S. 20 14 47.1 23.5 17.6 11.8 2.9
Li et al.30 China 83 6 N.S. 44 39 18.1 6.0 1.2 7.8 6.0
Xu et al.31 China 90 N.S. N.S. 39 51 50.0 19.0 3.0 6.0 1.0
Wu et al.32 China 80 0 0 39 41 47.5 0.0 +31.2 6.2 1.2
Yang et al.33 China 149 0 0 81 68 34.9 0.0 +18.7 6.0 0.7
Liu et al.34 China 3 N.S. N.S. 2 1 33.3 0.0 0.0 33.3 33.3
Lei et al.35 China 34 15 7 14 20 58.8 58.8 20.6 23.5 2.9
Feng et al.36 China 476 N.S. 38 271 205 43.1 0.0 8.0 10.3 4.6
Yuan et al.37 China 27 N.S. 10 12 15 48.1 19.0 11.0 22.0 0.0
Mo et al.38 China 155 N.S. N.S. 86 69 45.8 23.9 9.7 9.7 3.2
Wang et al.39 China 116 11 7 67 49 44.0 37.1 0.0 15.5 0
Zhang et al.40 China 221 23 12 108 113 35.3 24.4 10 10 2.7
Guo et al.41 China 256 45 43 91 165 73.0 32.6 11.2 15.0 2.1
Richardson et al.42 USA 5700 373 553 3437 2263 93.9 56.6 11.1 33.8 5.4
Chow et al.43 USA 74439 1069 2112 N.S. N.S. 3.6 0.0 9.0 10.9 9.2
Young et al.44 Singapore 18 2 0 9 9 27.8 N.S. N.S. N.S. N.S.
Gupta et al.45 India 21 N.S. N.S. 14 7 28.6 23.8 0.00 14.2 0.0
Grasselli et al.46 Italy 1591 1591 N.S. 1304 287 65.5 49.0 21.0 17.0 4.0
Du et al.47 China 85 N.S. 85 23 62 68.2 37.6 11.8 22.4 2.5
CDC Korea48 Korea 7755 N.S. 66 37 29 96.8 47.6 15.9 36.5 17.5
ICU = Intensive Care Unit; M = Male; F = Female; Co. % = Percentage of patients with comorbidities; H % = Percentage of Chronic 
Heart Disease; CV % = Percentage of Cardiovascular Disease; D % = Percentage of Diabetes; COPD % = Percentage of Chronic 
Obstructive Pulmonary Disease; CDC = Center for Disease Control and Prevention; + = Cardiovascular and Cerebrovascular 
Disease; N.S. = Not Specified
Rev Inst Med Trop São Paulo. 2020;62:e43
Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2
Page 5 of 13
(10.1%) in China. This study also included 21 cases from 
India, 54 from South Korea, and 18 from Singapore, 
representing less than 1% of the total patients included.
The analysis of the general population affected 
by COVID-19 indicated a 42% pooled prevalence of 
comorbidities (95% CI: 25-60; weight 100%). In China, the 
geographical distribution analysis showed a 43% prevalence 
of comorbidities (95% CI: 37-48; weight 89.4%), followed 
by the USA with 8% (95% CI: 7-8; weight 5.34%), India 
29% (95% CI: 14-50; weight 2.59%), and Singapore 28% 
(95% CI: 12 -51; weight 2.58%) (Figure 2).
Among those who had one or more previous diseases, 
there was a total of 16,222 comorbidities. Hypertension 
was the most prevalent in 32% (95% CI: 31-33; weight 
6.54%), followed by diabetes 22% (95% CI: 21-23; weight 
6.57%), heart disease 13% (95% CI: 13-14; weight 6.62%), 
and Chronic Obstructive Pulmonary Disease (COPD) 8% 
(95% CI: 7-8; weight 6.65%). In addition to these, other 
comorbidities were also assessed, such as kidney disease 
(5%), cancer (3%), asthma (3%), liver disease (2%), stroke 
(2%), immunodeficiencies (2%), and others (8%). The 
pooled prevalence with 95% CI values for each disease are 
shown in Table 2.
Prevalence of comorbidities in ICU patients
Of the six studies that conducted descriptions of the 
epidemiological and clinical profiles in patients admitted 
to the ICU, five divided the data according by sex. In these 
five studies, 1,661 patients were described6,11,13,36,48. Among 
these patients, 1,345 (81%) were male, 316 (19%) were 
female, and the age range was 46 to 63 years. The clinical 
characteristics of 2,730 patients were also described, 
indicating that 1,449 (53%) had one or more comorbidities. 
Figure 2 - Forest plot for a random-effect meta-analysis of comorbidities in all the patients affected by COVID-19.
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In total, there were 2,050 comorbidities among patients 
admitted to the ICU.
The pooled prevalence of comorbidities in ICU 
patients was 61% (95% CI: 42-80; weight 100%). The 
geographical distribution analysis showed a 69% prevalence 
of comorbidities (95% CI: 52-86; weight 61.09%) in 
China, followed by Italy, with 66% (95% CI: 63-68; weight 
19.47%), and the USA, with 33% (95% CI: 31-36; weight 
19.44%). The forest plot for a random-effect meta-analysis 
of comorbidities in patients admitted to ICUs by COVID-19, 
are shown in the Supplementary Figure S3.
The most prevalent comorbidities in the ICU population 
were hypertension 26% (95% CI: 25-29; weight 6.86%), 
heart disease 18% (95% CI: 16-19; weight 7.15%), 
diabetes 17% (95% CI: 16-19; weight 7.17%), and others 
17% (95% CI: 16-19; weight 7.15%). In addition to these 
diseases, patients with COPD (7%), cancer (5%), kidney 
disease (5%), liver disease (2%), and stroke (1%) were also 
evaluated. The pooled prevalence with the 95% CI values 
for each disease is shown in Table 2.
Prevalence of comorbidities among mortality cases
Eleven studies included descriptions of the 
epidemiological and clinical profiles of a total of 624 cases 
of mortality. In these studies, 394 patients were males and 
218 females, with an age range between 64 and 70 years. 
Among the 624 fatal cases, 415 of the patients had one or 
more previous diseases, totaling 751 comorbidities. The 
pooled prevalence of comorbidities among the fatal cases 
was 77% (95% CI: 68-86; weight 100%). Only two countries 
were analyzed in the geographical distribution: China, with 
71% (95% CI: 63-82; weight 76.79%) and Korea, with 92% 
(95% CI: 87-97; weight 23.21%) (Figure 3).
The most prevalent comorbidities in this population 
were hypertension 35% (95% CI: 25-29; weight 8.10%), 
diabetes 19% (95% CI: 16-22; weight 8.53%), heart disease 
17% (95 % CI: 14-20; weight 8.61%), and COPD 9% (95% 
CI: 7-11; weight 9.22%). In addition to these diseases, 
patients with cerebrovascular accident (6%), cancer (5%), 
kidney disease (4%), liver disease (3%), and other (2%) 
were also evaluated. The pooled prevalence with 95% CI 
values for each disease is shown in Table 2.
Odds ratio
The probability of a patient with comorbidity of dying 
from COVID-19, and the significance of this associations 
using the Fisher’s exact test, were calculated. The number 
of patients with comorbidities who died and those who 
Table 2 - Overall prevalence of comorbidities, in the group admitted to the ICU and in the fatal cases by COVID-19.
Comorbidity
Overall Prevalence ICUs Patients Fatal Cases
PP 95% CI W % PP 95% CI W % PP 95% CI W % 
Hypertension 32 31 - 33 6.54 27 25 - 29 6.86 35 31- 38 8.10
Chronic Heart Disease 13 13 - 14 6.62 18 18 - 19 7.15 17 14 - 20 8.61
Diabetes 22 21 - 23 6.57 17 15 -19 7.17 19 16 - 22 8.53
Malignancy 3 3 - 4 6.68 5 4 - 6 7.81 5 4 -7 9.22
COPD 8 7 - 8 6.65 7 6 - 8 7.67 9 7 -11 9.03
Asthma 3 3 - 3 6.69 0 0 - 0 0.00 0 0 - 0 0.00
Chronic Kidney Disease 5 5 - 5 6.67 5 6 - 8 7.81 4 3 - 6 9.29
Chronic Liver Disease 2 1- 2 6.7 2 4 - 6 8.01 3 2 - 4 9.42
Cerebrovascular Accident 2 1- 3 6.7 1 1 - 2 8.05 6 5 - 9 9.15
Immunodeficiency 2 2 - 3 6.69 2 1 - 3 7.97 0 0 - 0 0.00
Autoimmune Disease 0 0 - 0 6.71 0 0 - 0 8.12 0 0- 1 9.57
Cardiovascular and 
Cerebrovascular Accident
1 1 - 1 6.71 0 0 - 0 0.00 0 0 - 0 0.00
Digestive Disease 0 0 - 0 6.71 0 0 - 1 8.11 0 0 - 1 9.60
Peripheral Vascular Disease 0 1 - 0 6.71 0 0 -0 8.12 0 0 - 0 0.00
Other 8 7 - 8 6.65 18 16 - 19 7.15 2 1 - 3 9.48
Overall 7 5 - 8 100 7 6 - 8 100 9 6 - 11 100
ICU = Intensive Care Unit; PP = Pooled Prevalence; W = Weight; COPD = Chronic Obsctructive Pulmonary Disease; CI = Confidence 
Interval.
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survived, in addition to the patients without comorbidities 
who died and who survived, were used to calculate an odds 
ratio of 2.4 with 95% CI 1.7-3.3 and in the Fisher’s exact 
test the value of P < 0.0001.
DISCUSSION
This meta-analysis was based on 42 studies, including 
a large number of descriptions from China and the 
United States. Studies conducted in India, Italy, the 
United Kingdom, South Korea, and Singapore were also 
analyzed. A higher prevalence of male patients infected 
with COVID-19 was observed compared to females. This 
predisposition of the male sex was also observed in the 
diseases MERS-CoV and SARS-Co, which are also caused 
by viruses of the coronavirus family49,50. 
The pooled prevalence of comorbidities in the general 
population of patients affected by the new coronavirus 
(COVID-19) was 42% (95% CI: 26–59). China was 
the country with the highest prevalence, although there 
were also more studies analyzed from this country. 
However, it is important to highlight that two studies 
from the United States resulted in contrasting prevalence 
values (4% and 94%). Since the United States is the 
country that leads the statistics so far with the highest 
number of confirmed cases (more than one million) and 
deaths from coronavirus (more than seventy thousand), 
on May 8, 2020, it is of utmost importance to publish 
more data on the clinical characteristics of the disease in 
this country. 
The results of this study confirm that the prevalence of 
comorbidities increases as the patient’s clinical conditions 
worsens. In the general population affected by COVID-19, 
the prevalence of comorbidities was 42%, 61% among 
patients admitted to the ICU, and 77% among fatal cases. 
Males were the most affected in the three groups. On the 
other hand, the mean age also increases when we compare 
the group of patients in general with the group of fatal cases, 
as previously described among risk factors such as age, sex, 
and comorbidities4-7.
Regarding comorbidities, in the three groups analyzed 
(general population, admission to ICU, and fatal cases), 
hypertension was the most prevalent comorbidity, 
accounting for 32%, 26%, and 35%, respectively. In the 
general population, diabetes was the second-most prevalent 
(22%) comorbidity, followed by heart disease (13%) and 
COPD (8%). However, in patients admitted to the ICU, 
diabetes (17%) and heart disease (18%) showed similar 
values. The same phenomenon was observed in fatal cases, 
with diabetes (19%), and heart disease (17%) showing 
similar values. Considering that type 1 diabetes mellitus 
usually manifests during childhood or adolescence, type 2 
diabetes frequently manifests in adults, and heart diseases 
are more prevalent in older patients, one may think that the 
earlier onset of diabetes may account for it to rank second 
among the comorbidities in the general population affected 
Figure 3 - Forest plot for a random-effect meta-analysis of comorbidities in fatal cases of COVID-19.
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by COVID-19. On the other hand, the group of fatal cases 
is composed of predominantly older adults, a population 
in which hypertension, diabetes, and heart disease are 
prevalent. 
The odds ratio for any comorbidity was 2.4 with 95% 
CI 1.7-3.3 with a statistical significance of P < 0.0001. In 
other words, a patient with a comorbidity has 2.4 times the 
chance of dying from COVID-19 compared to a patient 
without a comorbidity. This may explain the high prevalence 
of comorbidities among fatal cases, 
In developing this study, we encountered several 
l imitat ions.  First ly,  not  al l  s tudies segregated 
epidemiological and clinical data (age, sex, percentage 
of comorbidity, and patients hospitalized in the ICU). 
Secondly, some studies classified comorbidities in the 
“Other” category, but only one study described which 
diseases were comprised in this category. Thirdly, since 
China is the primary focus of the rise of the pandemic, 
most of the studies included were from this country. No 
studies from Africa, Oceania, or Latin America were 
found. Finally, in meta-analyses, it is recommended that 
publication bias are always assessed by statistical methods. 
However, currently available methods, such as the funnel 
plot and the Egger regression test, are not considered 
useful tools in studies on proportions51.
One can conclude that the existence of comorbidities 
increases the probability of dying from COVID-19 by 2.4 
times compared to those who do not have pre-existing 
conditions. The most relevant comorbidities were shown 
to be hypertension, heart disease, and diabetes. Thus, 
comorbidities are more prevalent in the group of mortality 
cases when compared to the general population group. 
However, these conclusions are based on the evidence 
obtained, mostly from studies conducted in China. For 
this reason, studies describing the epidemiological and 
clinical profiles of COVID-19 cases in Africa, Oceania, 
and Latin America are recommended to clarify the 
behavior of this disease in these regions, and, thus, be 
able to apply effective measures aimed at safeguarding 
populations at risk. 
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